Compare RGCO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RGCO | SGMT |
|---|---|---|
| Founded | 1912 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.8M | 238.7M |
| IPO Year | N/A | 2023 |
| Metric | RGCO | SGMT |
|---|---|---|
| Price | $21.50 | $5.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.71 |
| AVG Volume (30 Days) | 11.8K | ★ 582.4K |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $95,334,212.00 | N/A |
| Revenue This Year | $6.03 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $16.53 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.06 | $1.73 |
| 52 Week High | $23.82 | $11.41 |
| Indicator | RGCO | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 37.49 | 39.65 |
| Support Level | $22.49 | $5.92 |
| Resistance Level | $22.49 | $6.33 |
| Average True Range (ATR) | 0.67 | 0.34 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 6.38 | 16.74 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.